(Kureczka/Martin Associates) LX211 (LUVENIQ; oral voclosporin) may become the first approved oral treatment capable of modifying the course of uveitis, otherwise inevitably associated with severe vision loss or substantial morbidity from steroid use.
Phase 2/3 trial results highlight LX211's ability to control inflammation characterizing this potentially blinding eye disease and significantly reduce its rate of recurrence.
Lux Biosciences plans to file for marketing approvals around year-end 2009 and early 2010 in the United States and Europe, respectively.